Inhibition of platelet aggregation with intravenous and oral administration of carboprostacyclin in man

Intravenous infusion of carboprostacyclin, a chemically stable analogue of prostacyclin (PGI2) resulted in ex-vivo inhibition of ADP-induced platelet aggregation at doses that did not produce significant changes in blood pressure or heart rate. Oral administration of relatively large doses of this compound also inhibited ex-vivo ADP-induced platelet aggregation but this was accompanied by headache, facial flush, tachycardia and changes in blood pressure.

Platelet and other effects of carboprostacyclin--a stable prostacyclin analogue

Carboprostacyclin, a chemically stable analogue of prostacyclin (PGI2) is 12.5 and 25.0 times respectively weaker than PGI2 in inhibiting ADP-induced aggregation of baboon and human platelets in vitro. Carboprostacyclin was also 28.5 times weaker as a vasodepressor than PGI2 in anaesthetised baboons. Intravenous and oral administration of carboprostacyclin in baboons resulted in ex-vivo inhibition of ADP-induced platelet aggregation at doses that did not produce changes in blood pressure or heart rate. Like PGI2, carboprostacyclin contracted guinea pig tracheal chain preparation in vitro but decreased histamine induced lung resistance in anaesthetised guinea pigs. Both PGI2 and carboprostacyclin relaxed the human respiratory tract smooth muscle in vitro.

Production of globules in mouse L cells penetrated with hamster sperms

Globule formation has been observed in long-term cultures of mouse L cells penetrated with hamster spermatozoa. These numerous, uniform, and spherical structures are approximately 10 micrometers in diameter when formed, and are positive to stains specific for proteins and nucleic acids. They may be produced either by sperms within their target cells or by the cells in response to penetration by the spermatozoa.